Reuters logo
BRIEF-‍Moody's says biosimilars market adoption faces hurdles but development continues apace​
September 28, 2017 / 4:17 PM / 2 months ago

BRIEF-‍Moody's says biosimilars market adoption faces hurdles but development continues apace​

Sept 28 (Reuters) - Moody‘s:

* ‍Moody’s says biosimilars market adoption faces hurdles but development continues apace​

* Moody’s says slow launch of Pfizer’s inflectra illustrates hurdles that biosimilar manufacturers face in gaining significant traction in the U.S.‍​

* Moody’s says potential changes to U.S. Medicare reimbursement could further encourage biosimilar adoption‍​

* ‍Moody’s says among biggest reasons for biosimilars’ slow adoption in U.S. is medicare reimburses providers at higher rates for innovator product use

* ‍Moody’s says Medicare reimburses providers at lower rates for switching to the biosimilar from innovator product

* ‍Moody’s says “biosimilar developers still have lots of room for growth, and we expect a number of new approvals over the next 12 to 18 months” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below